Novel Disulfidptosis-Related Gene Found to Regulate Tumor Immunity and Progression in Colorectal Cancer

Strategic Insights -

Research from Shanghai University of Traditional Chinese Medicine has identified a novel type of regulated cell death in colorectal cancer (CRC) called disulfidptosis. Scientists discovered that disulfide imbalance, which is caused by excessively high intracellular levels of cystine, can induce disulfidptosis. This study suggests that targeting disulfide imbalance could be a promising treatment approach for CRC.

Key Takeaways:

  • Researchers found that disulfidptosis is a novel type of regulated cell death induced by disulfide imbalance in CRC.
  • The study used The Cancer Genome Atlas (TCGA) datasets to classify disulfidptosis-related phenotypes in CRC patients.
  • Unsupervised clustering and gene set variation analysis were used to characterize the tumor microenvironment and identify prognostic genes.
  • Filamin A (FLNA) was identified as a pivotal regulator of disulfidptosis, and its functional impacts on tumor progression and immunotherapy response were further investigated.
  • The study found that disulfidptosis-related gene (DRG) signature can stratify CRC cases and identify prognostic DRGs.
  • FLNA inhibiting the DRG signature was found to suppress tumor cell migration and invasion, and reduce epithelial-mesenchymal transition (EMT).

Statistics:

  • The study analyzed TCGA datasets consisting of 826 CRC patients.
  • Unsupervised clustering identified two distinct subgroups of CRC cases based on the disulfidptosis-related signature (DRS).
  • The high-DRS subgroup correlated with poorer prognosis, elevated immunosuppressive cell activity, and reduced cytotoxic immune cell infiltration.
  • FLNA knockdown suppressed tumor cell migration and invasion in vitro by 32.5%.
  • FLNA inhibiting the DRG signature is found to reduce EMT by 25.2%.

Sources:

  • FLNA, a disulfidptosis-related gene, modulates tumor immunity and progression in colorectal cancer. Cellular & Molecular Biology Letters, 2025;30(1):92.
  • Cellular & Molecular Biology Letters, Bmc, Campus, 4 Crinan St, London N1 9XW, England.